Merck has traditionally eschewed large-scale M&A, but has been warming to the concept in recent years, with deals including its $11.5 billion takeover of Acceleron last year and its $2.75 billion ...

Takeda licenses late-stage polycythemia vera drug candidate rusfertide from Protagonist Therapeutics, adding to its rare blood disorder pipeline.

Listen live to BBC Radio 2 on BBC Sounds ...

Dr. Jay Gunawardana, a Sri lankan-born blood cancer researcher at the University of Queensland (Translational Research Institute in Brisbane, Australia) has received the prestigious American Society ...

This early analysis suggests that the combination of oral decitabine plus cedazuridine with venetoclax for higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia is safe in most ...

Bridget Christie & it's all gone a bit Pete Tong. Comic actress Bridget Christie pops by and Zoe's gone a bit Pete Tong ...